Thus, the number of superficial lung metastasis of mice that carried relapsed basal bladder cancer PDX and utilized Durvalumab was 7.2 ± 3.5 vs. 47.8 ± 6.1 in the subgroup of animals that received the vehicle alone (p = 0.001), and, similarly, IV introduction of anti-PD-L1 antibody lowered metastasis number in animals with relapsed p53 subtype of bladder cancer to 22.8 ± 5.4 vs. 63.4 ± 7.5 in the control group (p = 0.03). Here, CD274 is linked to urinary bladder carcinoma.